Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)
Macular Degeneration, Maculopathy, Age-Related, Age-Related Maculopathies
About this trial
This is an interventional treatment trial for Macular Degeneration focused on measuring AMD, anecortave acetate, wet AMD, age-related macular degeneration, Macular Degeneration, Maculopathy, Age-Related, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related
Eligibility Criteria
Inclusion Criteria: Diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye. Other protocol-defined inclusion criteria may apply. Exclusion Criteria: Under 50 years. Other protocol-defined exclusion criteria may apply.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Anecortave Acetate
Anecortave Acetate Vehicle
Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)
Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18)